Clinical Trial: Early Vedolizumab As First-Line for Immune-Related Colitis Therapy Trial

U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06841705) titled 'Early Vedolizumab As First-Line for Immune-Related Colitis Therapy Trial' on Feb. 11.

Brief Summary: The goal of this clinical trial is to compare the effectiveness and safety of Vedolizumab with a short course of steroids compared to standard course of steroids for the treatment of immune checkpoint inhibitor colitis (ICI colitis) in adults.

The main questions it aims to answer are:

* How many patients treated with Vedolizumab and a short course of steroids experience resolution of colitis at 8 weeks.

* How many patients treated with a standard course of steroids experience resolution of colitis at 8 weeks.

Participants will: ...